EN DE
STOCK COMPARISON

Hanmi Pharm Co vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Hanmi Pharm Co (128940) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Hanmi Pharm Co as the less overvalued of the two: Hanmi Pharm Co trades at KRW 392,500 versus a fair value of KRW 279,997 (-29%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).
Hanmi Pharm Co
128940.KO · KRW · Health Care
-29%
upside to fair value
overvalued
PriceKRW 392,500
Fair ValueKRW 279,997
Quality62/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-53%
upside to fair value
overvalued
Price¥54.62
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Hanmi Pharm CoJiangsu Hengrui Medicine Co
Valuation
—P/E (TTM)43.6×
—P/S (TTM)10.84×
—P/B5.76×
—EV/EBITDA33.0×
—PEG0.93×
0.6%Dividend yield0.4%
KRW 2,000Dividend per share¥0.20
Profitability
11%Net margin25%
12%Operating margin32%
14%Return on equity15%
6%Return on assets9%
Growth
1%Revenue growth (YoY)13%
5.1%Avg. growth/yr (3Y)13.9%
7.5%Avg. growth/yr (5Y)2.5%
Balance & size
0.07×Debt / equity—
$3BMarket cap$52B
healthyGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 2 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Hanmi Pharm Coof which business quality 60 · market factors 50 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 46
ProfitabilityMargins and returns on capital today
57
63
Quality GrowthAre margins and returns improving?
56
41
CashflowEarnings quality: real cash, not paper profit
38
82
Fin. StrengthBalance sheet, leverage, solvency risk
72
100
InvestmentDisciplined investing over empire-building
67
27
Low VolatilityCalm price path (market factor)
50
78
MomentumPrice trend over the last 3–12 months (market factor)
47
35
52W MomentumDistance to the 52-week high (market factor)
55
29
Net IssuanceBuybacks instead of dilution
79
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Hanmi Pharm Co

DCF ModelsKRW 280,364
Earnings-BasedKRW 161,836
MultiplesKRW 279,887
Asset-BasedKRW 66,035
Growth DCFKRW 212,256
Economic ProfitKRW 195,315
Growth EarningsKRW 213,637

23 of 24 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Hanmi Pharm Co
Bear KRW 159,126Fair Value KRW 279,997Bull KRW 367,718
KRW 392,500 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.62 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Hanmi Pharm Co · Health Care

Quality score62 · above median
Fair value upside-29% · above median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-53% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Hanmi Pharm Co as the less overvalued of the two: Hanmi Pharm Co trades at KRW 392,500 versus a fair value of KRW 279,997 (-29%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →
Hanmi Pharm Co · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Hanmi Pharm Co

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Medicine Co

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.